Frontiers In Clinical Drug Research Dementia Volume 2

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions - Tau-targeted therapy in Alzheimer's disease - history and current state - Emerging nanotherapeutic strategies in Alzheimer's disease - Implication of dehydroepiandrosterone on dementia related to oxidative stress - Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Frontiers in Clinical Drug Research - Dementia is a book series which presents comprehensive reviews about research on Dementia, - the loss of brain function associated with Alzheimer’s disease and other related medical conditions. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for dementia and related disorders. This volume includes the following reviews: - Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer’s Disease - Cholesterol in Brain Health and Pathologies - Advances in the Treatment of Mild Cognitive Impairment (MCI) and Dementia - Analytical Methods in Alzheimer’s Disease Drug Discovery - Targeting Alzheimer’s Disease through Nanomedicine - Current Challenges in Alzheimer’s Disease Research - Metals Linked to Alzheimer's Disease

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer’s disease research.

Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimers Disease research. The third volume of this series features research on -perfusional modifications in prodromal Alzheimer's disease, -BACE inhibition treatment, -frontotemporal dementia caused by progranulin mutations -evidence-based treatment for psychological symptoms of Alzheimer’s Diseas.

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD), a disease that causes dementia, or loss of brain function. This disease affects parts of the brain that affect memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer's disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in the field of Alzheimer's disease research. The eighth volume of this series features chapters covering critical discussions on new therapies for AD. The reviews in this volume include: - Novel Molecular Targets of Tauopathy; Therapeutic and Diagnostic Applications - The Therapy of Alzheimer's Disease: Towards a New Generation of Drugs - Could Antibiotics Be Therapeutic Agents in Alzheimer's Disease? - Use of Antipsychotics in Patients with Alzheimer's Disease - Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease - Potential Biological Mechanisms with Prophylactic Action in Rapid Cognitive Impairment in Late-Onset Alzheimer's Disease

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in neurology and allied disciplines. The twelfth volume of this series features these reviews: Chapter 1: Recent Drugs Tested in Clinical Trials for Alzheimer's and Parkinson's Diseases Treatment: Current Approaches in Tracking New Drugs Chapter 2: Neurobiology of Placebo: Interpreting Its Evolutionary Origin, Meaning, Mechanisms, Monitoring, and Implications in Therapeutics Chapter 3: Role of Gut Microbiota in Neuroinflammation and Neurological Disorders Chapter 4: The Role of Age in Pediatric Tumors of the Central Nervous System Chapter 5: Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities Chapter 6: Progress on the Development of Oxime Derivatives as a Potential Antidote for Organophosphorus Poisoning Readership Pharmaceutical scientists, clinical researchers, medical consultants and allied healthcare professionals interested in neuropharmacology and neurology

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each: Volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer's disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer's Disease research. The sixth: Volume of this series features chapters covering critical discussions on AD management and new therapies. The topics reviewed in This Volume include:- treatment of brain inflammation in Alzheimer's disease with traditional medicine- stem cell strategies for the modeling and therapy of Alzheimer's disease- retinal neurodegeneration in Alzheimer's disease- biological mass spectrometry for diagnosis of Alzheimer's disease...and more.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The fifth volume of this series features reviews that cover the following topics: -drug treatment for spinal cord injury -action tremors -natural products for Alzheimer’s disease treatment -non pharmacological approaches towards pain management -biosensors for detecting neurodegenerative diseases -NMDA receptor targeting -alkaloid antidepressants